Drotaverine Hydrochloride

Dose and dosage

Cattle

160-200 mg / animal.

Buffalo

160-200 mg / animal.

Horse

160-200 mg / animal.

Sheep and Goat

20-40 mg/animal.

Dog

20-40 mg/animal.

Cat

10-20 mg/animal.


Applications: Colic, Gastric Ulcer, Duodenal Ulcer, Spastic Constipation, meteorism, spasms of Cardia, Pyloric Sphincter Spasms, Spasms of biliary smooth muscles, Biliary Lithiasis, Cholecystitis, Uterine tetanic Contraction, Severe pains, Abortions imminence, Urethral lithiasis, Spasms of urinary tract Smooth muscles, Gastritis, Enteritis, Colitis, Pancreatitis
-----

 As antispastic in adjuvant treatment of digestive conditions (abdominal colic, gastric or duodenal ulcer, gastritis, enteritis, colitis, pancreatitis, spastic constipation, meteorism, spasms of cardia and pyloric sphincter, spasms of the biliary smooth muscles, biliary lithiasis, cholecystitis); spasms of urinary tract smooth muscles (renal urethral lithiasis, pyelitis, cystitis); genital disorders (uterine tetanic contractions, severe pains, abortion imminence) in dog, cat, horse and cattle. The spasmolytic action of the product also causes pain killing up to removal. 

 Severe hepatic, renal or cardiac failure. 

Drotaverine inhibits phosphodiesterase hydrolysing cAMP, thereby increasing cAMP concentration, decreasing Ca uptake of the cells and changing the distribution of calcium among the cells. It may also have minor allosteric calcium channel blocking properties. It is a smooth muscle relaxant.

 Levodopa (anti-perkinson effect may be decreased). 

 Arterial blood pressure may drop following too rapid intravenous injection. 

 There is no known case of teratogenicity in animal studies. However, the use of Drotaverine should be avoided during pregnancy and lactation 

 This drug is not to be administered to horses that are to be slaughtered for use in food. The administration is carried out only by the veterinarian or under his supervision. If administering by intravenous route, inject the product very slowly. Administer during pregnancy and lactation only afte previous assessment of the risk/benefit therapeutic ratio.